Application of a Total Antibody (TAb) Assay as a Companion Diagnostic (CDx) for AAV5 Gene Therapy
Time: 2:30 pm
day: Conference Day Two - Track 2 - PM
Details:
- Rationale for the selection of a Companion Diagnostic (CDx) for AAV5-based gene therapy for the treatment of Hemophilia A
- Validation of the AAV5 TAb assay as a companion diagnostic according to international standard and regulatory requirements
- AAV5 TAb CDx commercialization effort to ensure patients access to the validated and approved test
